- Home
- QCRH vs TNDM Comparison
QCRH vs TNDM Comparison
Compare QCRH & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QCRH | TNDM |
|---|---|---|
| Founded | 1993 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | QCRH | TNDM |
|---|---|---|
| Price | $87.02 | $18.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 18 |
| Target Price | ★ $98.50 | $28.33 |
| AVG Volume (30 Days) | 101.0K | ★ 1.8M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | ★ 11.62 | N/A |
| EPS | ★ 7.49 | N/A |
| Revenue | $165,999,610.00 | ★ $1,014,736,000.00 |
| Revenue This Year | $8.46 | $8.01 |
| Revenue Next Year | $5.59 | $12.14 |
| P/E Ratio | $11.66 | ★ N/A |
| Revenue Growth | ★ 20.72 | 7.93 |
| 52 Week Low | $60.83 | $10.00 |
| 52 Week High | $96.00 | $29.65 |
Technical Indicators
Market Signals| Indicator | QCRH | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 58.79 | 33.42 |
| Support Level | $87.01 | $17.71 |
| Resistance Level | $88.16 | $21.54 |
| Average True Range (ATR) | 2.27 | 1.30 |
| MACD | 0.73 | -0.67 |
| Stochastic Oscillator | 97.47 | 6.39 |
Price Performance
Historical ComparisonAbout QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.